251 related articles for article (PubMed ID: 18561248)
1. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis.
Hall CL; Daignault SD; Shah RB; Pienta KJ; Keller ET
Prostate; 2008 Sep; 68(13):1396-404. PubMed ID: 18561248
[TBL] [Abstract][Full Text] [Related]
2. Role of Wnts in prostate cancer bone metastases.
Hall CL; Kang S; MacDougald OA; Keller ET
J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
Hall CL; Bafico A; Dai J; Aaronson SA; Keller ET
Cancer Res; 2005 Sep; 65(17):7554-60. PubMed ID: 16140917
[TBL] [Abstract][Full Text] [Related]
4. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.
Hall CL; Zhang H; Baile S; Ljungman M; Kuhstoss S; Keller ET
Cancer Res; 2010 Dec; 70(23):9916-26. PubMed ID: 21098705
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
Thudi NK; Martin CK; Murahari S; Shu ST; Lanigan LG; Werbeck JL; Keller ET; McCauley LK; Pinzone JJ; Rosol TJ
Prostate; 2011 May; 71(6):615-25. PubMed ID: 20957670
[TBL] [Abstract][Full Text] [Related]
6. Effects of Dickkopf-1 (DKK-1) on Prostate Cancer Growth and Bone Metastasis.
Yuan S; Hoggard NK; Kantake N; Hildreth BE; Rosol TJ
Cells; 2023 Nov; 12(23):. PubMed ID: 38067123
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
Dai J; Hall CL; Escara-Wilke J; Mizokami A; Keller JM; Keller ET
Cancer Res; 2008 Jul; 68(14):5785-94. PubMed ID: 18632632
[TBL] [Abstract][Full Text] [Related]
8. Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases.
Aufderklamm S; Hennenlotter J; Leidenberger P; Rausch S; Hohneder A; Kühs U; Maas M; Schwentner C; Bedke J; Stenzl A; Todenhöfer T
Dis Markers; 2018; 2018():1874598. PubMed ID: 30116403
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.
Larson SR; Zhang X; Dumpit R; Coleman I; Lakely B; Roudier M; Higano CS; True LD; Lange PH; Montgomery B; Corey E; Nelson PS; Vessella RL; Morrissey C
Prostate; 2013 Jun; 73(9):932-40. PubMed ID: 23334979
[TBL] [Abstract][Full Text] [Related]
11. The role of Wnts in bone metastases.
Hall CL; Keller ET
Cancer Metastasis Rev; 2006 Dec; 25(4):551-8. PubMed ID: 17160558
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
13. Increased Dickkopf-1 expression in breast cancer bone metastases.
Voorzanger-Rousselot N; Goehrig D; Journe F; Doriath V; Body JJ; Clézardin P; Garnero P
Br J Cancer; 2007 Oct; 97(7):964-70. PubMed ID: 17876334
[TBL] [Abstract][Full Text] [Related]
14. High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients.
Rachner TD; Thiele S; Göbel A; Browne A; Fuessel S; Erdmann K; Wirth MP; Fröhner M; Todenhöfer T; Muders MH; Kieslinger M; Rauner M; Hofbauer LC
BMC Cancer; 2014 Sep; 14():649. PubMed ID: 25182503
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
16. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.
Zenzmaier C; Sampson N; Plas E; Berger P
Prostate; 2013 Sep; 73(13):1441-52. PubMed ID: 23765731
[TBL] [Abstract][Full Text] [Related]
17. A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model.
Goldstein SD; Trucco M; Bautista Guzman W; Hayashi M; Loeb DM
Oncotarget; 2016 Apr; 7(16):21114-23. PubMed ID: 27049730
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue.
Zenzmaier C; Untergasser G; Hermann M; Dirnhofer S; Sampson N; Berger P
Prostate; 2008 Apr; 68(5):540-7. PubMed ID: 18247400
[TBL] [Abstract][Full Text] [Related]
19. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.
Akfirat C; Zhang X; Ventura A; Berel D; Colangelo ME; Miranti CK; Krajewska M; Reed JC; Higano CS; True LD; Vessella RL; Morrissey C; Knudsen BS
J Pathol; 2013 Jul; 230(3):291-7. PubMed ID: 23420560
[TBL] [Abstract][Full Text] [Related]
20. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma.
Liu DJ; Xie YX; Liu XX; Huo YM; Yang MW; Fu XL; Liu W; Yang JY; Li J; Hua R; Liu PF; Sun YW; Zhang JF
Cell Cycle; 2017; 16(17):1622-1629. PubMed ID: 28749252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
